Scholar Rock Holding Corporation

NASDAQ:SRRK

Biotechnology

Healthcare
$48.00 +1.03%

+$0.49 today

Market cap
$5.86B
Beta
0.69
P/E (TTM)
-14.8
EPS (TTM)
-$3.21
52W Low $27.07High $52.19

Volume 2.77M

Average 1.46M

SRRK Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Scholar Rock Holding CorporationNASDAQ: SRRK

Stock-Based Compensation · Q3 FY2026 · quarter ended Sep 2026

Stock-based compensation dips below year-ago levels

Q3 FY2026 stock-based compensation of $17.91M fell 2.3% year over year, behind the +14.6% change in trailing-twelve-month stock-based compensation. Sequentially, it fell 8.9% from the prior quarter. Over 3 fiscal years it compounded at +39.7% a year.

Context

  • Stock-based compensation increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -2.3% toward the trailing-twelve-month pace of +14.6%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$17.91M-8.9% QoQ
Last fiscal yearDec 2025
$75.6M+106.4% YoY
LTMSep 2026
$75.24M+14.6% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.3%——
1 year+106.4%——
3-year CAGR+39.7%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
75.6M USD
Year-over-year change
+106.4%
4-year CAGR
+34.4%

Stock-Based Compensation vs competitors

How SRRK compares with its peers on the latest reported figures

  • SRRK's LTM Sep 2026 stock-based compensation of $75.24M is the 5th largest of the 11 companies compared; the peer median is $51.79M.
  • Its year-over-year change of +14.6% is the 4th highest of 11, against a peer median of -7.6%.
  • Stock-based compensation amounts to 13200.2% of revenue for SRRK, versus a peer median of 13.8%.
SRRK Competitors Peer median
Stock-Based Compensation for SRRK and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$132.29M +4.4%+10.1%13.8%
BBIOBridgeBio Pharma, Inc.LTM Jun 2026$111.95M -7.0%+13.3%15.7%
SRPTSarepta Therapeutics, Inc.LTM Mar 2026$111.37M -39.8%-19.1%5.1%
PTCTPTC Therapeutics, Inc.LTM Jun 2026$84.66M +15.0%-12.3%8.4%
SRRKScholar Rock Holding CorporationLTM Sep 2026$75.24M +14.6%+39.7%13200.2%
XENEXenon Pharmaceuticals Inc.LTM Sep 2026$64.29M +20.9%+38.1%—
DYNDyne Therapeutics, Inc.LTM Jun 2026$39.28M -8.1%+44.6%—
STOKStoke Therapeutics, Inc.LTM Mar 2026$26.2M -9.4%+12.2%81.7%
MAZEMaze Therapeutics, Inc.LTM Mar 2026$20.28M +92.0%+34.5%101.4%
BEAMBeam Therapeutics Inc.LTM Jun 2026$12.73M -111.5%+3.8%8.2%
EWTXEdgewise Therapeutics, Inc.LTM Sep 2026$1.76M -94.6%+47.1%—
Peer median (excluding SRRK) $51.79M-7.6%+12.7%13.8%

Competitors are the stored peer set for SRRK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(131.8M)(134.5M)(165.79M)(246.29M)(377.94M)
Depreciation & Amortization2.63M2.99M2.84M1.94M1.66M
Deferred Income Tax00000
Stock-Based Compensation23.15M27.7M27.14M36.63M75.6M
Change in Working Capital(28.44M)(34.39M)(10.61M)6.59M(1.05M)
Accounts Receivables00000
Inventory00000
Accounts Payables1.02M(251K)(529K)6.63M208K
Other Working Capital(29.46M)(34.14M)(10.09M)(36K)(1.26M)
Other Non-Cash Items7.67M5.51M1.19M186K1.7M
Operating Cash Flow(126.79M)(132.69M)(145.23M)(200.95M)(300.04M)
Capital Expenditures(5.25M)(1.06M)(71K)(98K)(602K)
Acquisitions (Net)00000
Purchases of Investments(60.44M)(300.63M)(290.8M)(293.16M)(98.01M)
Sales of Investments200M130M332M217.2M317.3M
Other Investing Activities0013K00
Investing Cash Flow134.32M(171.7M)41.14M(76.06M)218.69M
Debt Repayment24.98M(975K)0049.14M
Common Stock Issued13.1M195.32M97.71M324.41M179.26M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities6.87M492K4.87M28.61M0
Financing Cash Flow44.95M194.83M102.57M353.03M228.4M
Effect of Forex Changes0000(2K)
Net Change in Cash52.48M(109.56M)(1.51M)76.02M147.05M
Free Cash Flow(132.04M)(133.76M)(145.3M)(201.05M)(300.64M)

Scholar Rock Holding Corporation

NASDAQ:SRRK

Intrinsic Alpha fair value

Locked

Current Price

$48.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.